GlassScriptPhysician profile
Gregory-Thomas C Stanger
NPI 1215565262
$5,349.90
in general payments reported to CMS, 2019-2025
22 companies · $3,157 in 2025
The $3,157 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $86.52 · 2023: $403 · 2024: $1,703 · 2025: $3,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,666 · Education: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,665.88 |
| Education | $597.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,091.84 | 2024-2025 | Impella |
| Medtronic, INC. | $610.88 | 2024-2025 | Symplicity G3, Ffrangio, Onyx Frontier |
| Abbott Laboratories | $552.77 | 2025 | Ensite, Gallant, Dragonfly Opstar |
| Lantheus Medical Imaging, INC. | $429.39 | 2023-2025 | Definity |
| Shockwave Medical, INC | $357.69 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biosense Webster, INC. | $326.59 | 2025 | Carto 3 |
| Boston Scientific Corporation | $280.23 | 2023-2025 | Watchman Flx, Watchman Access System |
| Novo Nordisk INC | $251.85 | 2022-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $250.12 | 2024-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $211.63 | 2024-2025 | Sapien 3 Ultra Resilia |
| Kestra Medical Technology Services, INC. | $205.12 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.76 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $176.23 | 2025 | |
| Cvrx, INC. | $148.92 | 2025 | Barostim Neo System |
| Nevro Corp. | $116.37 | 2023 | Senza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.72 | 2025 | Verquvo |
| Genzyme Corporation | $26.27 | 2025 | |
| Bridgebio Pharma, INC. | $25.46 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $24.16 | 2024 | Inpefa |
| Pfizer INC. | $17.16 | 2025 | |
| Inogen, INC. | $13.54 | 2025 | |
| Chiesi USA, INC. | $13.20 | 2024 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory-Thomas Stanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.